CD90 Promotes Gastric Cancer Progression by Regulating SLC1A5-Mediated Glutamine Metabolism Through YY1

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• CD90 (THY1) is a cell surface glycoprotein implicated in malignant tumor development.
• It influences tumor cell proliferation, metastasis, angiogenesis, stemness, and metabolism.
• CD90 is a prognostic biomarker, but its role in gastric cancer (GC) glutamine metabolism is unclear.

Purpose of the Study:

• To investigate the role and mechanisms of CD90 in glutamine metabolism in gastric cancer cells.
• To elucidate how CD90 influences GC progression through metabolic pathways.

Main Methods:

• Investigated CD90's effect on glutamine metabolism in GC cells.
• Analyzed the interaction between CD90, YY1, and the SLC1A5 promoter.
• Assessed the impact on SLC1A5 transcription, glutamine metabolism, and ferroptosis.

Main Results:

• CD90 promotes GC progression by affecting glutamine metabolism via SLC1A5.
• CD90 facilitates YY1 binding to the SLC1A5 promoter, increasing its transcriptional level.
• This mechanism influences SLC1A5-mediated glutamine metabolism and ferroptosis in GC cells.

Conclusions:

• CD90 plays a significant role in regulating glutamine metabolism in GC cells.
• The CD90-YY1-SLC1A5 axis promotes GC progression and affects ferroptosis.
• Findings provide evidence for GC pathogenesis and potential therapeutic targets.